Incremental benefits of novel pharmaceuticals in the United Kingdom 75 4♣ In upcoming chapters, we will explore the potential value of data generated by expanded access programs through the lens of regulators, reimbursement bodies, and researchers. We will explore the often overlooked ‘research’ aspect of the expanded access ‘treatment’ pathway.
RkJQdWJsaXNoZXIy MTk4NDMw